Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ846850,5-0,41
KB840840,50,96
PKN64,2764,290,88
Msft421,45421,720,04
Nokia3,2893,2915-1,30
IBM190,09190,64-0,30
Mercedes-Benz Group AG73,8173,830,41
PFE27,7927,820,14
28.03.2024 12:28:00
Indexy online
AD Index online
select
AD Index online
 

Morphosys
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiMorphoSys AG
TickerMOR
Kmenové akcie:Ordinary Shares
RICMORG.DE
ISINDE0006632003
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 524
Akcie v oběhu k 29.02.2024 37 613 956
MěnaEUR
Kontaktní informace
UliceSemmelweisstr. 7
MěstoPLANEGG
PSČ82152
ZeměGermany
Kontatní osobaJulia Neugebauer
Funkce kontaktní osobySenior Director Investor Relations
Telefon4 989 899 270
Fax498989927222
Kontatní telefon498 989 927 179

Business Summary: MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, MorphoSys AG revenues decreased 14% to EUR238.3M. Net loss increased 26% to EUR189.7M. Revenues reflect License Fees segment decrease of 100% to EUR151K, Service Fees segment decrease of 22% to EUR15M, USA segment decrease of 15% to EUR211.5M, Europe (excluding Germany) segment decrease of 7% to EUR26.8M. Higher net loss reflects Finance Income - Balancing value decrease of 56% to EUR170.4M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Supervisory BoardMarc Cluzel6717.05.201817.05.2018
Chairman of the Management Board, Chief Executive OfficerJean-Paul Kress5801.09.201901.09.2019
Independent Deputy Chairman Member of the Supervisory BoardGeorge Golumbeski6501.01.2020
Chief Financial Officer, Member of the Management BoardLucinda Crabtree4431.08.202331.08.2023
Senior Vice President - Global Head of Human Resources, Member of the Executive CommitteeMaria Castresana-
Senior Vice President - Global Head of Technical Operations, Member of the Executive CommitteeLuisa Ciccarelli-
General Manager, Member of the Executive CommitteeJoe Horvat-
Member of the Executive Committee, Chief Research and Development OfficerTim Demuth-
Member of the Executive Committee, Chief Business OfficerBarbara Krebs-pohl-
Chief Legal Officer, Member of the Executive CommitteeCharlotte Lohmann-31.08.202330.05.2012